1. Home
  2. GNS vs TVRD Comparison

GNS vs TVRD Comparison

Compare GNS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.15

Market Cap

32.1M

Sector

Real Estate

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.02

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNS
TVRD
Founded
2002
2017
Country
Singapore
United States
Employees
N/A
12
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.1M
27.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GNS
TVRD
Price
$0.15
$2.02
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
1.9M
6.5M
Earning Date
03-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$156.26
N/A
Revenue Next Year
$35.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$1.50
52 Week High
$1.28
$43.65

Technical Indicators

Market Signals
Indicator
GNS
TVRD
Relative Strength Index (RSI) 33.67 38.25
Support Level N/A $1.50
Resistance Level $0.23 $4.32
Average True Range (ATR) 0.01 0.30
MACD -0.00 -0.10
Stochastic Oscillator 18.45 2.39

Price Performance

Historical Comparison
GNS
TVRD

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: